Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 N-acetylcysteine: A potential treatment for substance use disorders.

Literature DB >> 30016376

N-acetylcysteine: A potential treatment for substance use disorders.

Rachel L Tomko¹, Jennifer L Jones², Amanda K Gilmore³, Kathleen T Brady⁴, Sudie E Back⁵, Kevin M Gray⁵.

Abstract

Entities: Chemical Disease Gene Species

Year: 2018 PMID： 30016376 PMCID： PMC5993450

Source DB: PubMed Journal: Curr Psychiatr ISSN： 1537-8276

× No keyword cloud information.

46 in total

1. Quitting smoking among adults--United States, 2001-2010.

Authors:
Journal: MMWR Morb Mortal Wkly Rep Date: 2011-11-11 Impact factor: 17.586

2. Mortality risks associated with environmental tobacco smoke exposure in the United States.

Authors: Brian Rostron
Journal: Nicotine Tob Res Date: 2013-07-13 Impact factor: 4.244

3. A Double-Blind, Randomized, Controlled Pilot Trial of N-Acetylcysteine in Veterans With Posttraumatic Stress Disorder and Substance Use Disorders.

Authors: Sudie E Back; Jenna L McCauley; Kristina J Korte; Daniel F Gros; Virginia Leavitt; Kevin M Gray; Mark B Hamner; Stacia M DeSantis; Robert Malcolm; Kathleen T Brady; Peter W Kalivas
Journal: J Clin Psychiatry Date: 2016-11 Impact factor: 4.384

Review 4. Performance and Side Effects of Supplementation with N-Acetylcysteine: A Systematic Review and Meta-Analysis.

Authors: Kate Rhodes; Andrea Braakhuis
Journal: Sports Med Date: 2017-08 Impact factor: 11.136

5. The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: a double-blind controlled, crossover study.

Authors: Seyed Ghafur Mousavi; Mohammad Reza Sharbafchi; Mehrdad Salehi; Mohammad Peykanpour; Naeemeh Karimian Sichani; Mohammad Maracy
Journal: Arch Iran Med Date: 2015-01 Impact factor: 1.354

Review 6. Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders.

Authors: Douglas J Roberts-Wolfe; Peter W Kalivas
Journal: CNS Neurol Disord Drug Targets Date: 2015 Impact factor: 4.388

Review 7. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.

Authors: John Slattery; Nihit Kumar; Leanna Delhey; Michael Berk; Olivia Dean; Charles Spielholz; Richard Frye
Journal: Neurosci Biobehav Rev Date: 2015-05-06 Impact factor: 8.989

8. Alcoholism and alcohol abstinence: N-acetylcysteine to improve energy expenditure, myocardial oxidative stress, and energy metabolism in alcoholic heart disease.

Authors: Fábio Rodrigues Ferreira Seiva; Juliana Fujihara Amauchi; Katiucha Karolina Ribeiro Rocha; Geovana Xavier Ebaid; Gisele Souza; Ana Angélica Henrique Fernandes; Ana Catarina Cataneo; Ethel Lourenzi Barbosa Novelli
Journal: Alcohol Date: 2009-12 Impact factor: 2.405

9. Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial.

Authors: Michelle Bernardo; Seetal Dodd; Clarissa S Gama; David L Copolov; Olivia Dean; Kristy Kohlmann; Susan Jeavons; Ian Schapkaitz; Murray Anderson-Hunt; Ashley I Bush; Michael Berk
Journal: Acta Neuropsychiatr Date: 2009-10 Impact factor: 3.403

10. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers.

Authors: Jon E Grant; Brian L Odlaug; Samuel R Chamberlain; Marc N Potenza; Liana R N Schreiber; Christopher B Donahue; Suck Won Kim
Journal: J Clin Psychiatry Date: 2014-01 Impact factor: 4.384

10 in total

1. Pharmacological Treatment of Youth Substance Use Disorders.

Authors: Lindsay M Squeglia; Matthew C Fadus; Erin A McClure; Rachel L Tomko; Kevin M Gray
Journal: J Child Adolesc Psychopharmacol Date: 2019-04-22 Impact factor: 2.576

2. Impaired frontostriatal functional connectivity among chronic opioid using pain patients is associated with dysregulated affect.

Authors: Patrick A McConnell; Eric L Garland; Jon-Kar Zubieta; Roger Newman-Norlund; Shannon Powers; Brett Froeliger
Journal: Addict Biol Date: 2019-04-04 Impact factor: 4.280

3. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.

Authors: Rachel L Tomko; Nathaniel L Baker; Caitlyn O Hood; Amanda K Gilmore; Erin A McClure; Lindsay M Squeglia; Aimee L McRae-Clark; Susan C Sonne; Kevin M Gray
Journal: Psychopharmacology (Berl) Date: 2019-11-11 Impact factor: 4.530

4. N-acetylcysteine for the treatment of comorbid alcohol use disorder and posttraumatic stress disorder: Design and methodology of a randomized clinical trial.

Authors: Sudie E Back; Kevin Gray; Elizabeth Santa Ana; Jennifer L Jones; Amber M Jarnecke; Jane E Joseph; James Prisciandaro; Therese Killeen; Delisa G Brown; Linda Taimina; Ebele Compean; Robert Malcolm; Julianne C Flanagan; Peter W Kalivas
Journal: Contemp Clin Trials Date: 2020-02-19 Impact factor: 2.226

5. Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis.

Authors: Kenneth Blum; Jag Khalsa; Jean Lud Cadet; David Baron; Abdalla Bowirrat; Brent Boyett; Lisa Lott; Raymond Brewer; Marjorie Gondré-Lewis; Gregory Bunt; Shan Kazmi; Mark S Gold
Journal: Front Psychiatry Date: 2021-03-30 Impact factor: 4.157

Review 6. Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities.

Authors: Mark D Namba; Jonna M Leyrer-Jackson; Erin K Nagy; M Foster Olive; Janet L Neisewander
Journal: Front Neurosci Date: 2021-04-15 Impact factor: 4.677

7. Synaptic Zn²⁺ potentiates the effects of cocaine on striatal dopamine neurotransmission and behavior.

Authors: Juan L Gomez; Jordi Bonaventura; Jacqueline Keighron; Kelsey M Wright; Dondre L Marable; Lionel A Rodriguez; Sherry Lam; Meghan L Carlton; Randall J Ellis; Chloe J Jordan; Guo-Hua Bi; Oscar Solis; Marco Pignatelli; Michael J Bannon; Zheng-Xiong Xi; Gianluigi Tanda; Michael Michaelides
Journal: Transl Psychiatry Date: 2021-11-08 Impact factor: 6.222